Pelthos Therapeutics Inc.
PTHS- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001919246
In the last 90 days, Pelthos Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $37.4M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Pelthos Therapeutics Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 9 | 5 | −4 |
| Shares | 595.9K | 147.9K | −448.0K (−75.2%) |
| Value | $846.2K | $187.3K | −$658.9K (−77.9%) |
New holders (1)
Institutions that held Pelthos Therapeutics Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 136,712 | $172.3K | 0.00% |
Sold out (5)
Institutions that held Pelthos Therapeutics Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Ikarian Capital, LLC | 440,849 | $626.0K |
| Boothbay Fund Management, LLC | 130,754 | $185.7K |
| Wealth Enhancement Advisory Services, LLC | 10,400 | $14.8K |
| Tradewinds Capital Management, LLC | 200 | $284 |
| Barclays PLC | 54 | $77 |